SCHEMBL4817806

SCHEMBL4817806

CCOP(=O)(CC(=O)Nc1ccccc1C)OCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 7/20 0.53
▸ ALOX12 P18054 1/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ RAB9A P51151 3/20 0.50
▸ NPC1 O15118 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ HDAC3 O15379 1/20 0.49
▸ HDAC4 P56524 1/20 0.49
▸ HDAC1 Q13547 1/20 0.49
▸ HDAC7 Q8WUI4 1/20 0.49
▸ HDAC2 Q92769 1/20 0.49
▸ HDAC10 Q969S8 1/20 0.49
▸ HDAC11 Q96DB2 1/20 0.49
▸ HDAC8 Q9BY41 1/20 0.49
▸ HDAC6 Q9UBN7 1/20 0.49
▸ HDAC9 Q9UKV0 1/20 0.49
▸ HDAC5 Q9UQL6 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12497355 0.88 KDM4E (0.47) HPGDSMN1; SMN2RAB9AMAPTMAPK1
SCHEMBL13653517 0.85 GAA (0.51) HPGDSMN1; SMN2RAB9ANPC1MAPT
SCHEMBL31345023 0.84 MEN1 (0.51) SMN1; SMN2MAPTMAPK1LMNAHDAC3
SCHEMBL10952765 0.80 NPSR1 (0.53) HPGDALOX12SMN1; SMN2RAB9ANPC1
SCHEMBL28463477 0.80 GAA (0.48) MAPTLMNAALDH1A1HSD17B10POLB
SCHEMBL15483137 0.80 LMNA (0.41) HPGDSMN1; SMN2MAPK1LMNAALDH1A1
SCHEMBL13653001 0.79 ALDH1A1 (0.51) HPGDMAPTMAPK1LMNAALDH1A1
SCHEMBL16766556 0.76 PTK2 (0.38) SMN1; SMN2MAPTMAPK1POLBKDM4E
SCHEMBL28046922 0.76 GAA (0.44) SMN1; SMN2MAPTMAPK1ALDH1A1HSD17B10
SCHEMBL1818573 0.76 HPGD (0.68) HPGDALOX12SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740579-B1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBVIE INC (US) 2015-08-19 — — EP disclosed
US-7468371-B2 Tricyclic pyrazole kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-12-23 — — US disclosed
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors ABBVIE INC. 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors PRKDC, PRKACA, PIK3C3 HPGD 2092/4885ALOX12 4617/4885SMN1; SMN2 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback